Dr. Schreiber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
University of Colorado
Denver, CO 80202
Education & Training
University of ColoradoResidency, Internal Medicine, 2018 - 2021- University of Colorado School of Medicine Anschutz Medical CampusClass of 2018
Certifications & Licensure
- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 2 citationsOvercoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.Stephen G Smoots, Anna R Schreiber, Marilyn M Jackson, Stacey M Bagby, Adrian T A Dominguez
Breast Cancer Research. 2024-03-01 - 1 citationsMajor cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based che...Savannah Roy, Stephanie Lakritz, Anna R Schreiber, Elizabeth Molina Kuna, Cathy J Bradley
European Journal of Cancer. 2024-01-01 - 4 citationsFirst-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.Anna R Schreiber, Jodi A Kagihara, Bradley R Corr, S Lindsey Davis, Christopher Lieu
Cancers. 2023-12-23
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
